IHVR-19029

IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC 50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir improves the antiviral efficacy. In Vitro IHVR-19029 efficiently inhibits Bovine viral diarrhea virus (BVDV), Tacaribe virus (TCRV) and Dengue virus (DENV) with EC 50 s of 0.25, 0.74, and 1.25 μM, respectively. The combination of IHVR-19029 and Favipiravir synergistically inhibits the replication of Yellow fever and Ebola viruses in cultured cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo IHVR-19029 (25-75 mg/kg; I.p.; twice daily for 10 days) inhibits EBOV and MARV infection in mice. IHVR-19029 (5 mg/kg; i.v.) has AUC, C 0 , T 1/2 , CL and V d values of 1383 μg*h/mL, 1.79 μg/mL, 1.2 hours, 3.49 L/h/kg, and 3.0 L/kg, respectively. IHVR-19029 (75/5/5 mg/kg; p.o./i.m./i.p.) has AUC values of 945/1839/983 μg*h/mL, C max values of 0.26/1.23/1.33 μg/ml, T max values of 2.1/0.1/0.17 hours, and F values of 4.6/71/133%, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c mice (12 week 233 of age) (MARV infection)Dosage: 25, 75 mg/kg Administration: I.p.; twice daily, until 10 days Result: Significant protection of Marburg virus (MARV) induced death were observed. Animal Model: C57B1/6 mice (8–12 week of age) (EBOV infection)Dosage: 25, 75 mg/kg Administration: I.p.; twice daily for 10 days Result: Significant survival were observed. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet